James Crowe Jr.
Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.
Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.
Jul. 19, 2018—Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body.
Apr. 26, 2018—Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.
Apr. 12, 2018—The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.
Jan. 11, 2018—The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.
Dec. 14, 2017—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI).